Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RO7502175
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
RO7502175 is a humanized, afucosylated immunoglobulin G1 (IgG1) monoclonal antibody targeting C-C chemokine receptor 8 (CCR8). It is designed to selectively eliminate CCR8-positive regulatory T cells (Tregs) within the tumor microenvironment via enhanced antibody-dependent cellular cytotoxicity (ADCC), thereby reducing immunosuppression and potentially enhancing antitumor immune responses. The drug is being developed for use in solid tumors, both as monotherapy and in combination with checkpoint inhibitors such as atezolizumab. Preclinical studies have shown selective depletion of CCR8+ Tregs, minimal cytokine release, and a favorable safety profile[1][5][7].
- Other names
- anti-CCR8 monoclonal antibody RO7502175anti-CCR-8 monoclonal antibody RO7502175anti-CCR 8 monoclonal antibody RO7502175
02
Targets
CCR8
Beyond the preview
Go deeper on RO7502175.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RO7502175.